Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses

Fernando, Germain J. P., Chen, Xianfeng, Primero, Clare A., Yukiko, Sally R., Fairmaid, Emily J., Corbett, Holly J., Frazer, Ian H., Brown, Lorena E. and Kendall, Mark A. F. (2012) Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. Journal of Controlled Release, 159 2: 215-221. doi:10.1016/j.jconrel.2012.01.030

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Fernando, Germain J. P.
Chen, Xianfeng
Primero, Clare A.
Yukiko, Sally R.
Fairmaid, Emily J.
Corbett, Holly J.
Frazer, Ian H.
Brown, Lorena E.
Kendall, Mark A. F.
Total Author Count Override 9
Title Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses
Journal name Journal of Controlled Release   Check publisher's open access policy
ISSN 0168-3659
1873-4995
Publication date 2012-04-30
Sub-type Article (original research)
DOI 10.1016/j.jconrel.2012.01.030
Volume 159
Issue 2
Start page 215
End page 221
Total pages 7
Place of publication Amsterdam, Netherlands
Publisher Elsevier
Collection year 2013
Language eng
Formatted abstract
Many vaccines make use of an adjuvant to achieve stronger immune responses. Alternatively, potent immune responses have also been generated by replacing the standard needle and syringe (which places vaccine into muscle) with devices that deliver vaccine antigen to the skin's abundant immune cell population. However it is not known if the co-delivery of antigen plus adjuvant directly to thousands of skin immune cells generates a synergistic improvement of immune responses. In this paper, we investigate this idea, by testing if Nanopatch delivery of vaccine – both the antigen and the adjuvant – enhances immunogenicity, compared to intramuscular injection. As a test-case, we selected a commercial influenza vaccine as the antigen (Fluvax 2008®) and the saponin Quil-A as the adjuvant. We found, after vaccinating mice, that anti-influenza IgG antibody and haemagglutinin inhibition assay titre response induced by the Nanopatch (with delivered dose of 6.5 ng of vaccine and 1.4 μg of Quil-A) were equivalent to that of the conventional intramuscular injection using needle and syringe (6000 ng of vaccine injected without adjuvant). Furthermore, a similar level of antigen dose sparing (up to 900 fold) – with equivalent haemagglutinin inhibition assay titre responses – was also achieved by delivering both antigen and adjuvant (1.4 μg of Quil-A) to skin (using Nanopatches) instead of muscle (intramuscular injection). Collectively, the unprecedented 900 fold antigen dose sparing demonstrates the synergistic improvement to vaccines by co-delivery of both antigen and adjuvant directly to skin immune cells. Successfully extending these findings to humans with a practical delivery device – like the Nanopatch – could have a huge impact on improving vaccines.
Keyword Needle-free vaccines
Dose sparing
Skin immunization
Adjuvants
Microneedles
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 30 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 33 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 22 Mar 2012, 11:16:27 EST by Mark Kendall on behalf of Aust Institute for Bioengineering & Nanotechnology